The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily. Each year, about 40% of the ...

GlaxoSmithKline is to invest £275 ... an aseptic sterile facility to manufacture existing and new biopharmaceutical drugs. A site manufacturing active ingredients site for HIV and vaccines ...

(WHTM) — A global biopharma company just ... expand its long-time Lancaster County manufacturing facility. During a press ...

Working out of 12 manufacturing sites, the company distributed 767 million vaccine doses across more than 160 countries in 2021. More than ten million people received one of GSK’s meningococcal ...

(MENAFN) British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is ...

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx w ...